Thumb arthritis sufferers: could a double injection be the key to less pain?
NCT ID NCT03431584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether a mix of two common injections—cortisone and hyaluronic acid—works better than cortisone alone for thumb arthritis pain. 150 adults with moderate to severe pain took part. The goal was to see if the combination provides more relief.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
150 people
The number who actually took part.
- Started
-
May 2018
- Finished
-
Dec 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults, ≥ 40 years * Pain located at the root of the thumb (near the wrist) and awakened by direct pressure and movement * Pain resistant to well-conducted medical treatment, with analgesics, NSAIDs, icing with pain (analog visual scale) ≥ 4 for more than 3 months * Radiological findings (kapandji face + profile incidence) typical of rhizarthrosis, stage II or III of Eaton and Litter, with at least 2 of the following 5 radiological elements observed on the trapeziometacarpal joint: * marginal osteophyte * pinching of the joint space * sclerosis of the subchondral space * subchondral kyst * absence of osteopenia * Patient with the ability to understand the protocol and signed informed consent * Patient receiving social security Exclusion Criteria: * Known allergy to any of the products (corticosteroids or hyaluronic acid) including its excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol) * Change of analgesic treatment within 4 weeks before inclusion. * Patients with symptomatic bilateral rhizarthrosis * Scaphoid-trapezial arthrosis * Local or general infection * Severe coagulation disorders, ongoing anticoagulant therapy * severe and / or uncontrolled hypertension * Earlier local surgery * Associated inflammatory rheumatism * Tendinopathy of De Quervain, thumb to jump associated * Infiltrations earlier than 6 months * Diabetes imbalanced * Live vaccines * Severe water and / or sodium retention (hypernatremia), particularly in cases of heart failure, decompensated liver failure (edema and ascites failure) * Pregnant or lactating women * Immunocompromised or hemodialysis patients * Patients under guardianship, trusteeship, or deprived of liberty * Patients participating in another clinical research protocol involving a drug or medical device * Patients unable to follow the protocol, according to the judgment of the investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rhizarthrosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH Cholet
Cholet, 49300, France
-
CH Le Mans
Le Mans, 72037, France
-
CHD Vendée
La Roche-sur-Yon, 85925, France
-
CHU Nantes
Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.